CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
BACKGROUND/AIMS: Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI). Because PPIs are metabolized by CYP2C19 in the liver, we investigated whether a patient's CYP2C19 genotype was associated with symptomatic recurrence...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 65; no. 7; pp. 693 - 699 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Jul2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |